BioHedge Weekly
13D/13G filings from 18 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
Get in Touch
Interested in this coverage?
Reach out with questions or to discuss what you're tracking.
or email [email protected]
Weekly Filing Volume
Filings This Week
| Fund / Company | Ownership & Type |
|---|---|
RA Capital Management Werewolf Therapeutics, Inc. (HOWL) | 6.0% -1.5 13D/A [SEC] |
BVF Partners L.P. Kymera Therapeutics, Inc. (KYMR) | 6.3% -2.2 13D/A [SEC] |
EcoR1 Capital Fulcrum Therapeutics, Inc. (FULC) | 9.0% New 13G [SEC] |
EcoR1 Capital Fulcrum Therapeutics, Inc. (FULC) | 9.0% New 13G [SEC] |
RA Capital Management Solid Biosciences Inc. (SLDB) | 11.9% +2.0 13D/A [SEC] |
OrbiMed Enliven Therapeutics (ELVN) | 9.5% -1.4 13D/A [SEC] |
Fairmount Funds Management LLC Apogee Therapeutics, Inc. (APGE) | 10.0% 13D/A [SEC] |
Fairmount Funds Management LLC Spyre Therapeutics, Inc. (SYRE) | 10.0% 13D/A [SEC] |
RA Capital Management Werewolf Therapeutics, Inc. (HOWL) | 7.5% -3.1 13D/A [SEC] |
New Positions
Funds disclosing more than 5% ownership in a company for the first time.
| Fund / Company | Ownership & Type |
|---|---|
EcoR1 Capital Fulcrum Therapeutics, Inc. (FULC) | 9.0% SC 13G [SEC] |
EcoR1 Capital Fulcrum Therapeutics, Inc. (FULC) | 9.0% SC 13G [SEC] |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses more than 5% ownership in a company for the first time.
We track 18 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.